Tonix Pharmaceuticals Holding Corp. (TNXP) Fair Value 2026

TNXP · Biotechnology · 2026-08-27

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.9 /10

32 fundamental signals · 1 models active

Value Trap Risk

LOW (32/100)

Quick Summary — As of 2026-08-27, Tonix Pharmaceuticals Holding Corp. (TNXP) trades at $13.56. QOC: 5.9/10. Value Trap Risk: 32/100 (LOW). 1/13 models active.

Key Facts

Ticker: TNXP
Price: $13.56
Quality Score: 5.9/10
Value Trap Risk: 32/100
Models Active: 1/13
Last Updated: 2026-08-27

Strength: 1 independent models provide multi-angle coverage

Risk: Majority of models suggest overvaluation

What Fair Value Does Each Model Give TNXP?

1 Intrinsic Value Models vs. Current Price ($13.56)

Core Models (Unlocked)
Model	Fair Value	Upside
ML-RIV Intrinsic · High Conviction	$2.97	-78.1%

All Models Active

All 1 models are displayed above.

What Is Tonix Pharmaceuticals Holding Corp. (TNXP) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Tonix Pharmaceuticals Holding Corp.'s intrinsic value is estimated at $2.97. Trading at its current price of $13.56, the valuation engine raises significant caution: 1 of 1 models flag downside risk, projecting a median implied return of -78.1%.

What Do the Models Say About TNXP?

1 of 13 models are currently active for TNXP. All 1 active models suggest the stock trades above fair value. See which stocks rank higher →

How Does TNXP Rank in Biotechnology?

Among 620 Biotechnology stocks, TNXP ranks #153 by Quality of Company score. CirclFi's QOC score of 5.9/10 evaluates 32 fundamental signals. A score of 5.9 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

The Biotechnology sector introduces analytical considerations specific to biotech businesses. For Tonix Pharmaceuticals Holding Corp., metrics like clinical trial success rate provide important context that general-purpose valuation models may underweight.

Is TNXP a Value Trap?

CirclFi's Value Trap algorithm assigns TNXP a score of 32/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Tonix Pharmaceuticals Holding Corp.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Tonix Pharmaceuticals Holding Corp. scores 5.9 out of 10 on our 32-signal quality assessment, a solid rating that maintains reasonable quality metrics with some areas for improvement. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every TNXP valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across TNXP's 1 active models, average confidence is 60%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Tonix Pharmaceuticals Holding Corp. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

ATNMActinium Pharmaceuticals, Inc.QOC 6.0 ABEOAbeona Therapeutics Inc.QOC 5.9 CYTKCytokinetics, IncorporatedQOC 6.0 RYTMRhythm Pharmaceuticals, Inc.QOC 5.9 ISCOInternational Stem Cell CorporationQOC 6.0 SLNSilence Therapeutics plcQOC 5.9 CELCCelcuity Inc.QOC 5.0 SGMTSagimet Biosciences Inc.QOC 4.4 PLRZPolyrizon Ltd.QOC 1.9 EXELExelixis, Inc.QOC 9.6 INCYIncyte CorporationQOC 9.5

Read investment analysis: ATNM · ABEO · CYTK · RYTM · ISCO · SLN · CELC · SGMT · PLRZ · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to TNXP?

7 companies across all industries closest to TNXP’s Quality of Company score of 5.9/10.

AKAa.k.a. Brands Holding Corp.QOC 5.9 ZSQRZ Squared Inc.QOC 5.9 COMPCompass, Inc.QOC 5.9 VELOVelo3D, Inc.QOC 5.9 FGCOFinancial Gravity Companies, Inc.QOC 5.9 BQBoqii Holding LimitedQOC 5.9 NVDANVIDIA CorporationQOC 10.0

Read investment analysis: AKA · ZSQR · COMP · VELO · FGCO · BQ · NVDA

Where Does TNXP Sit in CirclFi's Biotechnology Rankings?

TNXP is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Tonix Pharmaceuticals Holding Corp.’s Valuation?

What is Tonix Pharmaceuticals Holding Corp.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Tonix Pharmaceuticals Holding Corp. (TNXP). The Quality of Company score is 5.9/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is TNXP overvalued or undervalued right now?

At $13.56, 0 of 1 active models suggest TNXP may be undervalued, while 1 indicate potential overvaluation. The assessment depends on which methodology best fits Tonix Pharmaceuticals Holding Corp.'s business model in Biotechnology.

What does a Quality of Company score of 5.9 mean for TNXP?

Tonix Pharmaceuticals Holding Corp.'s QOC of 5.9/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on TNXP?

CirclFi analyzes TNXP with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is TNXP a value trap in 2026?

Tonix Pharmaceuticals Holding Corp.'s Value Trap score is 32/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Tonix Pharmaceuticals Holding Corp. (TNXP) a Quality of Company score of 5.9/10 across 32 fundamental signals as of 2026-08-27.” Source: circlfi.com/stock/TNXP/ · Methodology

Primary sources for this TNXP valuation

Financial statements: Tonix Pharmaceuticals Holding Corp. 10-K and 10-Q filings on SEC EDGAR (CIK 0001430306) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for TNXP as of 2026-08-27; valuations recomputed 2026-08-27.